Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | NOS1 | P29475 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5841721 | 0.93 | L3MBTL1 (0.53) | DRD4DRD2DRD3ATML3MBTL1 | |
| SCHEMBL6132620 | 0.91 | ATM (0.51) | DRD4DRD2DRD3ATML3MBTL1 | |
| SCHEMBL6753836 | 0.91 | ATM (0.51) | DRD4DRD2DRD3ATML3MBTL1 | |
| SCHEMBL6132633 | 0.91 | ATM (0.51) | DRD4DRD2DRD3ATML3MBTL1 | |
| SCHEMBL6132362 | 0.91 | ATM (0.51) | DRD4DRD2DRD3ATML3MBTL1 | |
| SCHEMBL2530176 | 0.90 | KCNA3 (0.50) | DRD4DRD2DRD3L3MBTL1KDM4E | |
| SCHEMBL15512103 | 0.88 | DRD4 (0.44) | DRD4DRD2DRD3ATML3MBTL1 | |
| SCHEMBL1697534 | 0.88 | KDM4E (0.50) | DRD4DRD2DRD3ATML3MBTL1 | |
| SCHEMBL17445905 | 0.87 | ATM (0.60) | DRD4DRD2DRD3ATML3MBTL1 | |
| SCHEMBL18235025 | 0.87 | DRD4 (0.57) | DRD4DRD2DRD3ATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250388581-A1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12331052-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| CN-109790136-B | Furan cross-linking group-containing polymer and application thereof | 广州华睿光电材料有限公司 | 2024-01-12 | — | — | CN | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-3560917-B1 | POLYMER CONTAINING FURAN CROSSLINKING GROUP AND USE THEREOF | GUANGZHOU CHINARAY OPTOELECTRONIC MAT LTD (CN) | 2023-12-20 | — | — | EP | disclosed |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | YALE UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | YALE UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| WO-2005104745-A2 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-11-10 | — | — | WO | disclosed |
| EP-1575495-A2 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050113580-A1 | Amide compounds and methods of using the same | SMITHKLINE BEECHAM CORP | 2005-05-26 | — | — | US | disclosed |
| WO-2003082205-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| WO-1996015672-A1 | FUNGICIDAL COMPOSITION | ZENECA LIMITED (GB) | 1996-05-30 | — | — | WO | disclosed |
| WO-1996015671-A1 | HERBICIDES | ZENECA LIMITED (GB) | 1996-05-30 | — | — | WO | disclosed |
| US-5453443-A | Antiallergens, antiinflammatory | MERCK FROSST CANADA, INC. (CA) | 1995-09-26 | — | — | US | disclosed |
| EP-0342664-B1 | 2,2-disubstituted benzopyran leukotriene-D4 antagonists | SEARLE & CO (US) | 1993-12-15 | — | — | EP | disclosed |
| US-5093353-A | 2,2-di-substituted benzopyran leukotriene-D4 antagonists | G. D. SEARLE & CO. (US) | 1992-03-03 | — | — | US | disclosed |
| EP-0342664-A2 | 2,2-disubstituted benzopyran leukotriene-D4 antagonists | G.D. Searle & Co. (US) | 1989-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388581-A1 | ORGANIC COMPOUNDS | OPRD1, OPRM1, HTR2C | DRD4 29/4885DRD2 7/4885DRD3 24/4885 |
| US-12331052-B2 | Organic compounds | OPRD1, OPRK1, OPRM1 | DRD4 37/4885DRD2 13/4885DRD3 27/4885 |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | DRD4 4654/4885DRD2 4522/4885DRD3 4621/4885 |
| US-20050113580-A1 | Amide compounds and methods of using the same | NR1H2, NR1H3, PPARA | DRD4 3396/4885DRD2 3504/4885DRD3 2584/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | DRD4 4620/4885DRD2 4554/4885DRD3 4699/4885 |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | DRD4 4654/4885DRD2 4522/4885DRD3 4621/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | DRD4 4742/4885DRD2 4637/4885DRD3 4610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.